nach oben

Journal of Clinical Immunology

Erschienen in:

01.10.2011 | Letter to the Editor

Incidence of Infection is Inversely Related to Steady-State (Trough) Serum IgG Level in Studies of Subcutaneous IgG in PIDD

verfasst von: Melvin Berger

Erschienen in: Journal of Clinical Immunology | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Results from seven studies of four subcutaneous IgG preparations in patients with primary immune deficiencies show that the incidence of infection is inversely related to the steady-state IgG level. Maintaining higher IgG levels may be beneficial, and no given level is necessarily adequate for all patients.

Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am. 2008;28:779–802.PubMedCrossRef

Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007;21:105–16.PubMedCrossRef

Bhole MV, Burton J, Chapel H. Self-infusion programmes for immunoglobulin replacement at home: feasibility, safety and efficacy. Immunol Allergy Clin North Am. 2008;28:821–32.PubMedCrossRef

Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am. 2008;28:803–19.PubMedCrossRef

Thepot S, Malphettes M, Gardeur A, Galicier L, Asli B, Karlin L, et al. Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG Levels. J Clin Immunol. 2010;30(4):602–6.PubMedCrossRef

Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol. 2011;139:133–41.PubMedCrossRef

Desai SH, Chouksey A, Poll J, Berger M. A pilot study of equal doses of 10% IGIV given intravenously or subcutaneously. J Allergy Clin Immunol. 2009;124:854–6.PubMedCrossRef

Jolles S, Bernatowska E, De Gracia J, Borte M, Cristea V, Peter HH, et al. Efficacy and safety of IgPro20 in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clinical Immunology, 2011 (in press)

Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125:1354–60.PubMedCrossRef

10.

Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137:21–30.PubMedCrossRef

11.

Quinti I, Sorensina A, Guerra A, Rondell R, Spadaro G, Agonstini C, et al. Effectiveness of immunoglobulin replacement therapy in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol. 2011. doi:10.1007/s10875-011-9511-0.

12.

Gardulf A, Nicolay U, Asensio O, Bernatowska E, Böck A, Carvalho BC, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies—a prospective, multi-national study. J Clin Immunol. 2006;26:177–85.PubMedCrossRef

13.

Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M, Subcutaneous IgG Study Group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26:265–73.PubMedCrossRef

14.

Hagan JB, Fasano MB, Spector S, Wasserman R, Melamed I, Rojavin MA, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010;30:734–45.PubMedCrossRef

15.

Wasserman RL, Irani AM, Tracy J, Tsoukas C, Stark D, Levy R. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol. 2010;161:518–26.PubMedCrossRef

16.

Wasserman RL, Melamed I, Kobrynski L, Strausbaugh SD, Stein MR, Sharkhawy M, et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol 2011 (in press)

17.

Berger M, Murphy E, Riley P, Bergman GE, VIRTUE Trial Investigators. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin. G S Med J. 2010;103:856–63.CrossRef

18.

US Food and Drug Administration. Guidance for industry: safety, efficacy and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. Available at: http://www.fda.gov/cber/gdlns/igivimmuno.htm

19.

Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008;122:210–2.PubMedCrossRef

Titel: Incidence of Infection is Inversely Related to Steady-State (Trough) Serum IgG Level in Studies of Subcutaneous IgG in PIDD
verfasst von: Melvin Berger
Publikationsdatum: 01.10.2011
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 5/2011
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-011-9546-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Incidence of Infection is Inversely Related to Steady-State (Trough) Serum IgG Level in Studies of Subcutaneous IgG in PIDD

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2011

Rapid Disease Progression in HIV-1-Infected Men Who Have Sex with Men Is Negatively Correlated with Peripheral Plasmacytoid Dendritic Cell Counts at the Early Stage of Primary Infection

Severe Combined Immunodeficiency in Greek Children over a 20-Year Period

The Relationship Between Hypogammaglobulinemia, Monoclonal Gammopathy of Undetermined Significance and Humoral Immunodeficiency: a Case Series

Active Immunological Profile Is Associated with Systemic Sjögren’s Syndrome

Defective T Cell Chemotaxis to Sphingosine 1-Phosphate and Chemokine CCL21 in Idiopathic T Lymphocytopenia

KRN/I-Ag7 Mouse Arthritis Is Independent of Complement C3

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin